TY - JOUR
T1 - Survival after reoperation for recurrent glioblastoma
AU - Woodroffe, Royce W.
AU - Zanaty, Mario
AU - Soni, Neetu
AU - Mott, Sarah L.
AU - Helland, Logan C.
AU - Pasha, Arham
AU - Maley, Joan
AU - Dhungana, Neha
AU - Jones, Karra A.
AU - Monga, Varun
AU - Greenlee, Jeremy D.W.
N1 - Publisher Copyright:
© 2020
PY - 2020/3
Y1 - 2020/3
N2 - Determining which patients will benefit from reoperation for recurrent glioblastoma remains difficult and the impact of the volume of FLAIR signal hyperintensity is not well known. The primary purpose of this study is to analyze the impact of preoperative volume of FLAIR hyperintensity on prognosis. 37 patients who underwent a reoperation for recurrent glioblastoma after initial gross total resection followed by standard chemoradiation were retrospectively reviewed. Volumetric analysis of preoperative MR images from the initial and second surgery was performed and correlated with clinical data. Survival probabilities were estimated using the Kaplan-Meier method and Cox regression to assess the effect of risk factors on time to reoperation (TTR), progression-free survival (PFS) after reoperation, and overall survival (OS). The volumes of FLAIR signal hyperintensity prior to the initial surgery and reoperation were not associated with prognosis. TTR and OS were significantly affected by the preoperative enhancement volume at the initial surgery, with increasing volumes yielding poorer prognosis. Patients with tumor in critical/eloquent areas were found to have a worse prognosis. Median TTR was 11 months, median PFS after reoperation was 3 months, and OS in patients undergoing a reoperation was 21 months. The results suggest FLAIR signal change seen in patients with glioblastoma does not influence time to reoperation, progression-free survival, or overall survival. These findings suggest the amount of FLAIR signal change should not greatly influence a surgeon's decision to perform a second surgical resection compare to other factors, and when appropriate, aggressive surgical intervention should be considered.
AB - Determining which patients will benefit from reoperation for recurrent glioblastoma remains difficult and the impact of the volume of FLAIR signal hyperintensity is not well known. The primary purpose of this study is to analyze the impact of preoperative volume of FLAIR hyperintensity on prognosis. 37 patients who underwent a reoperation for recurrent glioblastoma after initial gross total resection followed by standard chemoradiation were retrospectively reviewed. Volumetric analysis of preoperative MR images from the initial and second surgery was performed and correlated with clinical data. Survival probabilities were estimated using the Kaplan-Meier method and Cox regression to assess the effect of risk factors on time to reoperation (TTR), progression-free survival (PFS) after reoperation, and overall survival (OS). The volumes of FLAIR signal hyperintensity prior to the initial surgery and reoperation were not associated with prognosis. TTR and OS were significantly affected by the preoperative enhancement volume at the initial surgery, with increasing volumes yielding poorer prognosis. Patients with tumor in critical/eloquent areas were found to have a worse prognosis. Median TTR was 11 months, median PFS after reoperation was 3 months, and OS in patients undergoing a reoperation was 21 months. The results suggest FLAIR signal change seen in patients with glioblastoma does not influence time to reoperation, progression-free survival, or overall survival. These findings suggest the amount of FLAIR signal change should not greatly influence a surgeon's decision to perform a second surgical resection compare to other factors, and when appropriate, aggressive surgical intervention should be considered.
KW - Contrast enhancement
KW - MRI FLAIR signal change
KW - Overall survival
KW - Progression free survival
UR - http://www.scopus.com/inward/record.url?scp=85078347457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078347457&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2020.01.009
DO - 10.1016/j.jocn.2020.01.009
M3 - Article
C2 - 31987636
AN - SCOPUS:85078347457
SN - 0967-5868
VL - 73
SP - 118
EP - 124
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
ER -